AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

GOSS · NASDAQ · Biotechnology

Gossamer Bio

Develops inhaled seralutinib for pulmonary arterial hypertension and PH-ILD.

$0.1726

After-hours close+0.00 (+2.49%)

At close$0.1684(−1.00%)

Something off on this page? Send us feedback.

Profile

Gossamer Bio, Inc.GOSSHealth Care

Develops and seeks to commercialize inhaled seralutinib for PAH and PH-ILD. The clinical-stage portfolio is centered on that single program, with development and commercialization structured through a global collaboration with Chiesi.

Develops inhaled seralutinib, also called GB002, for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The small-molecule candidate inhibits PDGFR, CSF1R, and c-KIT and is the sole remaining clinical-development program following a restructuring that ended other candidate programs.

Leads global development for seralutinib in PAH and PH-ILD under a collaboration with Chiesi. In the United States, the companies share commercial profit and loss while Gossamer leads commercialization in those indications; Chiesi holds exclusive commercialization rights outside the United States and pays royalties on net sales. The regulatory path depends on FDA discussions concerning an NDA supported by an adequate and well-controlled investigation plus confirmatory evidence.

Company facts

CEOFaheem Hasnain

ListedFeb 8, 2019

ExchangeNASDAQ

HeadquartersSan Diego, CA

CountryUnited States

Employees162

CIK0001728117

ISINUS38341P1021

Key statistics

Market cap$83.2M

EPS (ttm)−$0.7000

P/E (ttm)−0.2430

ROE108.7%

P/B−0.4236

P/S1.56

Dividend yield—

Beta2.13vs XLV 0.45

Year to date −94.2% · Average volume (30d) 39.6M

Analysts

Price target, next 12 months$3.00+1,664.7%Median of 17 analysts · vs the Aug 28 close

ConsensusBuy10 of 17 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $0.1700

High$9.00+5,194.1%

Median$3.00+1,664.7%

Low$0.3000+76.5%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Jul 28, 2026	Leerink Partners	Upgrade	Market Perform	Outperform
Mar 23, 2026	Cantor Fitzgerald	Downgrade	Overweight	Neutral
Feb 24, 2026	Wedbush	Downgrade	Outperform	Neutral		$1
Feb 24, 2026	Barclays	Downgrade	Overweight	Underweight	$9	$0.30
Feb 24, 2026	Leerink Partners	Downgrade	Outperform	Market Perform

Earnings

EPS

Estimate−$0.07

ReportedDue Nov 4, 2026

Revenue

Estimate$10.7M

ReportedDue Nov 4, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 13, 2026Q2 FY26	−$0.12	−$0.08	+35.2%	$3.6M	$9.2M	+154.6%	−9.45%
May 18, 2026Q1 FY26	−$0.17	−$0.20	−17.6%	$4.7M	$17.0M	+263.2%	+3.32%
Mar 17, 2026Q4 FY25	−$0.20	−$0.21	−5.0%	$7.5M	$13.8M	+83.4%	−7.99%
Nov 5, 2025Q3 FY25	−$0.19	−$0.21	−10.5%	$7.5M	$13.3M	+76.6%	−2.53%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$9.9M	$11.5M	$13.3M	$13.8M	$17.0M	$9.2M
Gross profit	$9.9M	$11.5M	$13.3M	$13.8M	$16.7M	$9.2M
Operating income	−$36.8M	−$38.8M	−$49.1M	−$46.0M	−$44.9M	−$26.1M
Net income	−$36.6M	−$38.3M	−$48.2M	−$47.2M	−$46.7M	$16.9M
Diluted EPS	−$0.16	−$0.17	−$0.21	−$0.21	−$0.20	−$0.08
Gross margin	100.0%	100.0%	100.0%	100.0%	98.6%	100.0%
Operating margin	-372.2%	-337.4%	-369.4%	-333.6%	-264.6%	-282.2%

Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $114.7M · FY25 $48.5M

Revenue by product · FY24

License And Service$90.7M · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $57.0M · Total debt $39.1M · Total assets $76.9M · Shareholders' equity −$94.0M

Dividends

No dividends on record.

Ownership

Institutions 34.17%167.04M sharesInsiders 1.55%7.58M sharesOther 64.28%314.23M shares

Shares outstanding 488.85M · Float 128.76M · 26.3% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
683 Capital Management, LLC	49.87M	9.99%	13G	Jun 11, 2026
Context Capital Management, LLC	48.84M	9.90%	13G	Jun 9, 2026
DeepCurrents Investment Group LLC	37.67M	7.70%	13G	Jun 11, 2026
D. E. Shaw & Co., L.P.	29.13M	6.00%	13D	Aug 24, 2026
Opaleye Management Inc.	24.94M	5.10%	13G	Jul 29, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.